The stock market was overbought and due for a correction, Jim Cramer told his Mad Money viewers Friday. Now that correction is finally happening, led by the horrendous IPOs of SmileDirectClub (SDC) - Get Report , Peloton (PTON) - Get Report and other substandard deals.
Wednesday brings earnings from Lennar (LEN) - Get Report and Cramer said he remains a believer in the housing market. He was not so optimistic with Bed Bath & Beyond (BBBY) - Get Report , a stock he called "a nightmare."
Finally, on Friday, Cramer will be focused on the latest non-farm payroll numbers, which he called the most important metrics our government provides investors about the economy.
Save 57% during our fall sale: Join Jim Cramer's Action Alerts PLUS investment club to become a smarter investor. Click here to sign up and save.
Off the Tape: GoodRx
In his "Off The Tape" segment, Cramer spoke with Doug Hirsch, co-CEO of the privately-held GoodRx, the application that helps people save on their prescriptions.
Hirsch said there are huge gaps in how healthcare happens in the U.S., which is why GoodRx created their marketplace for prescriptions and is now expanding into the basic healthcare services that everyone needs. Their new service, GoodRx Care, helps people find the best prices and availability on basic medical services. He said too many times you can't even get in to see some doctors for weeks, while other great doctors right around the corner may be available today.
Hirsch explained that GoodRx coupons are accepted at all major drugstore chains and clinic providers.
Look to Foreign Pharma Companies
For the past year, the domestic pharma and biotech stocks have been gripped by fear, Cramer told viewers. Investors have been fearing increased regulations if the Democrats take the White House and are worried about more liability lawsuits. Does that mean investors should abandon the whole sector? Cramer said the best way to play pharma now is to look overseas.
AstraZeneca (AZN) - Get Report is a British pharmaceutical maker with less than 33% of its sales in the U.S. The company has promising drugs in their pipeline, and Cramer said the stock is very promising, too. Likewise with GlaxoSmithKline (GSK) - Get Report , a company working to transform itself by doubling down on its oncology business. Glaxo has five promising Phase III trials underway, yet trades for less than 14 times earnings with a 4.8% dividend yield.
Finally, Cramer recommended Novartis (NVS) - Get Report , the Swiss-based drugmaker that's also an Action Alerts PLUS holding. Like the others, Novartis only gets a third of its business from the U.S. and is also transforming its operations by spinning off its eyecare business and focusing on its strengths, like gene therapy. The company has 8% sale growth, but trades for 15 times earnings with a 3.2% dividend.
On Real Money, Cramer says you can't be in the money-losers even if they have the potential for high growth. Get more of Cramer's insights with a free trial subscription to Real Money.
ConAgra Gets its Groove Back
Cramer said ConAgra has been in a tailspin since December, when the company announced that its $11 billion acquisition of Pinnacle Foods wasn't going as well as expected. After the announcement, the stock plunged and after recovering slightly in the spring, shares have been largely trading sideways as integration issues continued.
Back in June, ConAgra indicated that it had begun making progress in fixing the Pinnacle acquisition, but those gains were overshadowed by temporary events.
This quarter however, ConAgra had finally gotten itself back on track, raising its guidance. With shares trading at just 13 times earnings with a 2.8% dividend yield, Cramer said the stock was a buy, as the worst is now behind it.
Winning Stocks With Room to Rise
In his "No-Huddle Offense" segment, Cramer said viewers who are looking for great stocks to buy right now should be looking at some of the biggest winners, but not to those who are at their highs.
Cramer said stocks like Apple (AAPL) - Get Report , Microsoft (MSFT) - Get Report and Procter & Gamble (PG) - Get Report are all up big for the year, but they're also at or just below their all-time highs. Meanwhile, stocks like Visa (V) - Get Report and American Express (AXP) - Get Report are a lot more attractive. American Express is down 8% from its highs, but the company just boosted its dividend by 10% and announced a big buyback. Shares also trade for just 13 times earnings, making them even more attractive.
Introducing TheStreet Courses: Financial titans Jim Cramer and Robert Powell are bringing their market savvy and investing strategies to you. Learn how to create tax-efficient income, avoid top mistakes, reduce risk and more. With our courses, you will have the tools and knowledge needed to achieve your financial goals. Learn more about TheStreet Courses on investing and personal finance here.
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
At the time of publication, Cramer's Action Alerts PLUS had a position in PEP, NVS, AAPL, MSFT.